Blueprint Medicines Corp
BPMC
ISIN null / Valor 27670715
Blueprint Medicines Corp
UMushroom community rating:
About company
Blueprint Medicines Corp is a global biopharmaceutical company dedicated to developing targeted therapies for patients with serious diseases, particularly in the areas of oncology, hematology, and allergy/inflammation. The company has successfully brought two medicines to market and maintains a robust pipeline of investigational treatments aimed at addressing the underlying causes of various conditions. Leveraging its deep biological expertise and advanced drug design capabilities, Blueprint Medicines focuses on precision medicine approaches to create innovative solutions. Additionally, the company supports its development efforts with comprehensive clinical and commercial infrastructure, enhancing its ability to advance and commercialize novel therapies effectively.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (29.09.2025):
Blueprint Medicines Corp reported strong financial results for the first quarter of 2025, achieving significant revenue growth and raising its AYVAKIT net product revenue guidance for the year. The company continues to advance its clinical pipeline while maintaining a robust cash position.
Revenue Growth
Blueprint Medicines Corp achieved AYVAKIT net product revenues of $149.4 million in Q1 2025, marking a 61% year-over-year increase. This includes $129.4 million from US sales and $20 million from international markets.
Guidance Increase
The company has raised its global AYVAKIT net product revenue guidance for 2025 to a range of $700 million to $720 million, driven by favorable sales mix and strong underlying growth fundamentals.
Clinical Progress
Blueprint initiated two proof-of-concept studies for BLU-808 in allergic rhinoconjunctivitis and chronic urticaria, advancing its pipeline in mast cell disorders. Additionally, the HARBOR study of elenestinib was progressed in indolent systemic mastocytosis.
Financial Position
The company's cash, cash equivalents, and investments increased to $899.8 million as of March 31, 2025, bolstered by the sale of its equity investment in IDRx, Inc. This strong cash position supports ongoing investments in prioritized programs and ensures financial sustainability.
Upcoming Milestones
Blueprint Medicines aims to achieve continued revenue growth for AYVAKIT, secure reimbursement in over 20 countries, and initiate additional clinical studies for BLU-808 in allergic asthma and MCAS throughout 2025.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
8361 M
Market cap (USD)
Daily traded volume (Shares)
88.48 / 85.95
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
